AAVnerGene is a leading biotech company specializing in the development of advanced gene therapy technologies utilizing the AAV platform. Situated in Rockville, Maryland, our state-of-the-art facilities span over 10,000 square feet, housing dedicated spaces for research and development as well as production capabilities. With a leadership team boasting over two decades of experience in the field of AAV gene therapy, along with numerous publications and patents, we are at the forefront of innovation.

Our objective is to enhance the accessibility of gene therapy by addressing the bottlenecks in AAV gene therapy.

We have introduced groundbreaking AAV production systems known as AAVone and AAVdual. AAVone system employs just a single plasmid for AAV packaging, resulting in a 2-4 fold increase in packaging efficiency. Conversely, the AAVdual system utilizes two plasmids for AAV vector packaging, simultaneously elevating production efficiency while preserving the flexibility to generate various AAV serotypes.
We’ve pioneered the ATHENA platform, encompassing ATHENA I, ATHENAII, and ATHENA III, to streamline the process of comparing, selecting, and evolving AAV capsids. ATHENA I is a recognized capsid library designed for the purpose of comparing and selecting the most promising AAV serotypes or variants. ATHENA II, on the other hand, is a random peptide insert library tailored for the development of novel AAV capsids with specific functionalities. Lastly, ATHENA III serves as a rational DNA shuffling library, enabling the creation of innovative hybrid AAV capsids through a deliberate approach.

As scientists ourselves, we are fueled by a profound passion to empower fellow researchers in achieving breakthroughs using the AAV platform for gene therapy. We take pride in providing a wide range of AAV products and comprehensive AAV services in AAV design, AAV packaging, AAV analysis, AAV optimization, and AAV capsid library design, construction, production, screening and evolution, to both academic institutions and companies. By collaborating with us, you gain access to our expertise and cutting-edge technologies to propel your research and therapeutic endeavors forward.

Together, let us pave the way for a future where gene therapy becomes accessible and transformative for all.

Contact us today to explore the vast possibilities of the AAV platform and embark on a journey of scientific discovery and impact.

We warmly welcome potential collaborators and investors to join us on this transformative journey. For inquiries and further information, kindly reach out to our esteemed President and CEO, Mr. Daozhan Yu, at daozhan.yu@aavnergene.com. Together, we can drive the future of gene therapy and bring meaningful impact to patients worldwide.